TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27693614
Drug: Cognitive-Behavioral Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Treatment (FFS/CBT)
Study: 27694141
Drug: HIF-2α inhibition
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIF-2α inhibition by small hairpin RNA or selective small molecule antagonist
Study: 27699253
Drug: Oral ruxolitinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ruxolitinib
Study: 27699634
Drug: Intravenous plasma-derived,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous plasma-derived, pasteurized, nanofiltered C1-inhibitor concentrate (pnfC1-INH; Berinert)
Study: 27701169
Drug: Treatment time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment time allocation
Study: 27703758
Drug: Remote cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote cognitive-behavioural therapy (CBT) - 6-12 sessions
Study: 27704266
Drug: Lenvatinib 12
Normalized name: lenvatinib 12 MG Daily Dose 30 Day Supply Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib 12 mg once daily (QD)
Study: 27707765
Drug: STEBVax (recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: STEBVax (recombinant staphylococcal enterotoxin B protein vaccine) at doses ranging from 0.01 μg to 20 μg
Study: 27707765
Drug: STEBVax (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: STEBVax (2.5 μg to 20 μg)
Study: 27708788
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of LLLT and lorcaserin
Study: 27709460
Drug: Concurrent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent treatment with the proton pump inhibitor pantoprazole (DE-P)
Study: 27709460
Drug: Overall effectiveness
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall effectiveness using either strategy or a combination
Study: 27710003
Drug: FORNET (forensic
Approvals — FDA: no, EMA: no, PMDA: no
Description: FORNET (forensic offender rehabilitation narrative exposure therapy)
Study: 27712711
Drug: RESQ-eD (twice
Approvals — FDA: no, EMA: no, PMDA: no
Description: RESQ-eD (twice daily for 7 days)
Study: 27713637
Drug: Sunitinib at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib at a starting dose of 50 mg/day on a 4-weeks-on/2-weeks-off schedule
Study: 27714595
Drug: Calcipotriol 50
Normalized name: Calcipotriol 50 microgram/g cutaneous cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol 50 µg/g and Betamethasone 0.5 mg/g aerosol foam
Study: 27716218
Drug: Community-based football
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-based football (one hour twice weekly for six months)
Study: 27716304
Drug: 20,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20,000 IU vitamin D daily for 14 days followed by 10,000 IU per day for 7 days
Study: 27716377
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clinical parameters and biomarker concentrations
Study: 27716819
Drug: Nintedanib (100,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib (100, 150, and 200 mg orally twice daily) combined with low-dose cytarabine (20 mg subcutaneous injection twice daily for 10 days)
Study: 27716819
Drug: Nintedanib combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nintedanib combined with low-dose cytarabine (LDAC)
Study: 27717384
Drug: Cleveland-Clinic Acute
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cleveland-Clinic Acute Renal Failure (CC-ARF) score
Study: 27719673
Drug: Knowledge of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge of aetiology, diagnosis, and treatment of pre-eclampsia and eclampsia among health care providers.
Study: 27719678
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of antihypertensives and MgSO by some staff nurses.
Study: 27720178
Drug: Plasma therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma therapy
Study: 27723665
Drug: Non-VKA oral
Normalized name: Tavist Non-Sedating Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-VKA oral anticoagulants (NOACs)
Study: 27724970
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of tranexamic acid (TxA) administered after the first blood sample was taken.
Study: 27725657
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (unmedicated)
Study: 27726853
Drug: Intensification of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensification of medical therapy (initiation of aspirin or initiation/increases in dose of ACE inhibitors, ARBs, statins, or β blockers)
Study: 27726853
Drug: No intensification
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intensification of medical therapy
Study: 27729313
Drug: Vemurafenib in
Normalized name: Product containing vemurafenib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vemurafenib in combination with irinotecan and cetuximab
Study: 27729766
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg ALA
Study: 27729766
Drug: 1,200 mg
Normalized name: lecithin 1,200 mg ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg ALA
Study: 27729766
Drug: Gastrointestinal prophylaxis
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrointestinal prophylaxis medications
Study: 27730010
Drug: SAR422459 gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SAR422459 gene therapy
Study: 27733159
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (moderate-intensity)
Study: 27733243
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg intravenously every 2 weeks until disease progression or treatment discontinuation
Study: 27733374
Drug: Cisplatin 30
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 30 mg/m² weekly with concurrent standard radiotherapy (60-66 Gy over 6-7 weeks) and panitumumab.
Study: 27733394
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D inadequacy (<50 nmol/L)
Study: 27733413
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral glucose tolerance test (OGTT) 75 g
Study: 27733413
Drug: New screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: New screening algorithm based on multivariable risk estimation using early OGTT 75 g and/or glyFn results
Study: 27736729
Drug: KB004 (anti-EphA3
Approvals — FDA: no, EMA: no, PMDA: no
Description: KB004 (anti-EphA3 monoclonal antibody) administered by intravenous infusion on days 1, 8, and 15 of each 21-day cycle in escalating doses.
Study: 27736729
Drug: KB004 (anti-EphA3
Approvals — FDA: no, EMA: no, PMDA: no
Description: KB004 (anti-EphA3 monoclonal antibody) administered by intravenous infusion.
Study: 27740633
Drug: Epigenetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epigenetic therapy (decitabine and panobinostat)
Study: 27741195
Drug: Contraceptive implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive implants (34% of participants)
Study: 27742908
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (AA), 1,000 mg daily, and prednisone (P), 5 mg twice daily
Study: 27747511
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) dose 6-<8 mg/week in biologic-naïve patients
Study: 27747511
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) dose in biologic-exposed patients
Study: 27747511
Drug: Increased MTX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased MTX doses
Study: 27747515
Drug: TCZ 4
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TCZ 4 mg/kg
Study: 27747515
Drug: TCZ 8
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: TCZ 8 mg/kg
Study: 27747585
Drug: Subcutaneous tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous tocilizumab (TCZ-SC) 162 mg weekly or every other week for up to 84 weeks
Study: 27748745
Drug: Withdrawal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withdrawal of PPARγ agonist rosiglitazone
Study: 27749456
Drug: Bevacizumab 15
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg every 3 weeks with 4 to 8 cycles of paclitaxel plus carboplatin, continued until progression or for up to 24 months.
Study: 27749456
Drug: Bevacizumab 15
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 15 mg/kg for more than 15 months.
Study: 27749456
Drug: Bevacizumab therapy
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab therapy beyond 15 months.
Study: 27751676
Drug: Selumetinib, 75-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selumetinib, 75-mg single dose
Study: 27751772
Drug: Antibiotic use
Normalized name: Antibiotics for systemic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic use during travel
Study: 27751941
Drug: fMRI data
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: fMRI data preparation techniques
Study: 27752787
Drug: Preoperative mFOLFOX6
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative mFOLFOX6 therapy (6 cycles)
Study: 27756258
Drug: Standard cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cytotoxic treatment
Study: 27756308
Drug: Trimethoprim-sulfamethoxazole (TS)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TS) prophylaxis, daily from 6 weeks of age until exclusion of HIV-infection after cessation of breastfeeding.
Study: 27757709
Drug: No endothelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No endothelin receptor antagonists
Study: 27760758
Drug: Blocking erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blocking erythropoietin (EPO)-EPO receptor (R) signaling
Study: 27760761
Drug: Triplex vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triplex vaccine (MVA encoding CMV antigens)
Study: 27761518
Drug: mHealth intervention
Normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth intervention (self-monitoring via daily text messages, wireless devices for weight and steps tracking, 4 motivational interviewing-based phone sessions)
Study: 27762283
Drug: HCV RNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV RNA cutoff of 6 million IU/mL
Study: 27763941
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRI) treatment with citalopram
Study: 27764686
Drug: Durvalumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (10 mg/kg every 2 weeks via intravenous infusion) with concurrent palliative RT
Study: 27765757
Drug: mFOLFOX6 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6 plus ramucirumab (8 mg/kg)
Study: 27765906
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy proposed to patients (clinical trial or registered drugs)
Study: 27765906
Drug: Targeted treatment
Normalized name: benzoyl peroxide 25 mg in 1 mL TOPICAL SWAB [SkinPharmacy Advanced Acne Therapy Targeted Treatment Wipes]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted treatment received
Study: 27765906
Drug: Genomic-driven treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genomic-driven treatment implementation
Study: 27766119
Drug: Trial medication
Normalized name: benzoyl peroxide Medicated Pad [Triaz]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trial medication (levothyroxine) for 24 weeks
Study: 27766602
Drug: Gene-Eden-VIR/Novirin (1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene-Eden-VIR/Novirin (1-4 capsules per day for 2-48 months)
Study: 27766602
Drug: Dose-response control
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose-response control group
Study: 27767222
Drug: Periodontal therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periodontal therapy (mechanical debridement plus 1 week of amoxicillin/metronidazole)
Study: 27767943
Drug: Equine-assisted occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Equine-assisted occupational therapy intervention
Study: 27767943
Drug: Conventional treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatments (control group not explicitly mentioned)
Study: 27768923
Drug: Triplet hepatic
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triplet hepatic artery infusion (HAI) and intravenous cetuximab (500 mg/m² cetuximab, 180 mg/m² irinotecan)
Study: 27768923
Drug: Triplet hepatic
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triplet hepatic artery infusion (HAI) and intravenous cetuximab
Study: 27771496
Drug: Rituximab 250
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab 250 mg (days -21 and -14)
Study: 27771496
Drug: Fludarabine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine 30 mg/m2
Study: 27771544
Drug: Nilotinib 400mg
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 400mg twice daily for 24 months
Study: 27771610
Drug: Tivozanib (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tivozanib (1.5 mg daily, 3 weeks on 1 week off, 28-day cycle)
Study: 27774033
Drug: Inhaled capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled capsaicin solution challenge
Study: 27774059
Drug: Music Upper
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Music Upper Limb Therapy-Integrated (MULT-I), 45-min intervention, twice a week for 6 weeks
Study: 27774495
Drug: OnabotulinumtoxinA treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: OnabotulinumtoxinA treatments
Study: 27775823
Drug: CALM-CBT (Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: CALM-CBT (Cognitive Behavioral Therapy)
Study: 27775823
Drug: CBT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT plus medication management
Study: 27775823
Drug: Higher CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher CBT dose
Study: 27776521
Drug: Artemether-lumefantrine (AL)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (AL) administered under direct observation with a fat intake consisting of ready-to-use therapeutic food (RUTF - Plumpy'Nut®), twice daily during 3 days.
Study: 27777606
Drug: Diet Rite
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet Rite Cola™ (18 mg sucralose, 18 mg acesulfame-potassium, 57 mg aspartame)
Study: 27777606
Drug: NNS in
Normalized name: trastuzumab-anns Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNS in water (0 mg, 68 mg, 170 mg, 250 mg sucralose)
Study: 27777612
Drug: Evidence-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based treatment of panic disorder
Study: 27778193
Drug: Sodium Oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Oxybate (SXB) 9 g/night
Study: 27778639
Drug: Droxidopa (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droxidopa (300 mg, 3 times a day)
Study: 27778639
Drug: Treatment-naive conditions
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-naive conditions
Study: 27779248
Drug: Intravenous busulfan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous busulfan (Bu)
Study: 27780903
Drug: Successful reperfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful reperfusion (defined as modified Treatment in Cerebral Ischemia grade of 2b to 3)
Study: 27781135
Drug: Brexpiprazole 1-3
Normalized name: brexpiprazole 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brexpiprazole 1-3 mg/day
Study: 27782373
Drug: Sofosbuvir/simeprevir plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir/simeprevir plus flat dose ribavirin (800 mg/d) for 12 weeks
Study: 27785036
Drug: Digital medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital medicine system (DMS) with sensor-embedded tablets of aripiprazole, 8-week treatment.
Study: 27787664
Drug: Interferon (IFN)-free
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN)-free treatment
Study: 27787778
Drug: Alogliptin (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin (12.5 mg and 25 mg doses)
Study: 27789147
Drug: Pfs25H-EPA/Alhydrogel® vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pfs25H-EPA/Alhydrogel® vaccine candidate
Study: 27789517
Drug: Adenosine diphosphate
Normalized name: Adenosine diphosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine diphosphate receptor inhibitors (ADPri) therapy
Study: 27789517
Drug: Early cessation
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early cessation of ADPri therapy
Study: 27789678
Drug: INCB039110 (selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB039110 (selective JAK1 inhibitor)
Study: 27791128
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with peptide 1 or 7 in combination with RFASE
Study: 27791128
Drug: Antibodies raised
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibodies raised with peptides 15 and 20
Study: 27791347
Drug: PF-06651600 (JAK3-selective
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06651600 (JAK3-selective inhibitor)
Study: 27793850
Drug: DMUC5754A (0.3-3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMUC5754A (0.3-3.2 mg/kg every 3 weeks)
Study: 27793850
Drug: DMUC5754A (0.8-1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMUC5754A (0.8-1.6 mg/kg weekly)
Study: 27796540
Drug: Elotuzumab monotherapy
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Elotuzumab monotherapy (10 or 20 mg/kg)
Study: 27796740
Drug: ASP0113 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP0113 (5 mg, five doses at intervals before and after HCT)
Study: 27797988
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of physical activity and normocaloric diet
Study: 27798346
Drug: Daily eating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily eating episodes (mean ± SD: 4.2 ± 1.3 times/d)
Study: 27798346
Drug: Daily eating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily eating episodes
Study: 27798550
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of TDF during labor (Cohort 1)
Study: 27798550
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg dose on days 0, 3 and 5 (Cohort 2)
Study: 27798550
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg maternal dose during labor, followed by 6 mg/kg infant dose on days 0, 3 and 5 (Cohort 3)
Study: 27799204
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg efavirenz (single oral dose)
Study: 27799230
Drug: Clopidogrel administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel administration for 7 days
Study: 27799506
Drug: Dabrafenib and
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib and NovoTTF-100A (Tumor Treatment Fields device)
Study: 27799506
Drug: NovoTTF-100A (Tumor
Approvals — FDA: no, EMA: no, PMDA: no
Description: NovoTTF-100A (Tumor Treatment Fields device) with concurrent radiation and chemotherapy (CCRT)
Study: 27799945
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at a fixed dose of 0.033 mg/kg/day for 260 weeks
Study: 27799945
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment at a fixed dose of 0.067 mg/kg/day for 260 weeks
Study: 27799945
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (both doses)
Study: 27799945
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (high dose)
Study: 27801315
Drug: JAK inhibitor
Normalized name: Janus-associated kinase (JAK) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: JAK inhibitor ruxolitinib
Study: 27801983
Drug: Hydrocortisone dosing
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone dosing frequency
Study: 27803005
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg daily
Study: 27805836
Drug: Lumacaftor/Ivacaftor (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumacaftor/Ivacaftor (200 mg lumacaftor/250 mg ivacaftor orally every 12 hours for 24 weeks)
Study: 27811504
Drug: Observation after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation after nephrectomy without adjuvant chemotherapy